UY32005A - Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a - Google Patents

Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a

Info

Publication number
UY32005A
UY32005A UY0001032005A UY32005A UY32005A UY 32005 A UY32005 A UY 32005A UY 0001032005 A UY0001032005 A UY 0001032005A UY 32005 A UY32005 A UY 32005A UY 32005 A UY32005 A UY 32005A
Authority
UY
Uruguay
Prior art keywords
derivatives
stratriene
bioisosters
include heterocyclic
phenolic ring
Prior art date
Application number
UY0001032005A
Other languages
English (en)
Inventor
Dr Dieter Heldmann
Dr Joachim Kuhnke
Dr Thorsten Blume
Dr Norbert Schmees
Dr Christiane Otto
Dr Tim Wintermantel
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of UY32005A publication Critical patent/UY32005A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0042—Nitrogen only
    • C07J71/0047—Nitrogen only at position 2(3)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Nuevos derivados de pirazolo-estrieno y triazolo-estrieno, composiciones farmacéuticas que los contienen y su uso en el tratamiento o la prevención de trastornos y enfermedades mediados por un receptor de estrógeno; y como agentes anticonceptivos, solos o en combinación con un progestógeno o un antagonista de un progestógeno. Los compuestos de la invención son moduladores selectivos del receptor de estrógeno.
UY0001032005A 2008-07-24 2009-07-23 Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a UY32005A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08161108A EP2147924A1 (en) 2008-07-24 2008-07-24 Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring

Publications (1)

Publication Number Publication Date
UY32005A true UY32005A (es) 2010-02-26

Family

ID=40329347

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032005A UY32005A (es) 2008-07-24 2009-07-23 Derivados de estratrieno que comprenden bioisósteros heterocíclicos para el anillo fenólico a

Country Status (24)

Country Link
US (1) US20110190246A1 (es)
EP (2) EP2147924A1 (es)
JP (1) JP2011528675A (es)
KR (1) KR20110036739A (es)
CN (1) CN102105484A (es)
AR (1) AR072533A1 (es)
AU (1) AU2009273494A1 (es)
BR (1) BRPI0915987A2 (es)
CA (1) CA2731634A1 (es)
CL (1) CL2011000153A1 (es)
CO (1) CO6351799A2 (es)
CR (1) CR20110045A (es)
DO (1) DOP2011000024A (es)
EA (1) EA201100226A1 (es)
EC (1) ECSP11010780A (es)
IL (1) IL210314A0 (es)
MA (1) MA32477B1 (es)
MX (1) MX2011000939A (es)
PE (1) PE20110402A1 (es)
SV (1) SV2011003817A (es)
TW (1) TW201008570A (es)
UY (1) UY32005A (es)
WO (1) WO2010009828A1 (es)
ZA (1) ZA201101445B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011092127A1 (en) * 2010-01-26 2011-08-04 Bayer Schering Pharma Aktiengesellschaft 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring
CA3178707A1 (en) * 2020-05-15 2021-11-18 Peng GU Pyrrolidine compound and use thereof
DE102022109556A1 (de) 2022-04-20 2023-10-26 Eberspächer Catem Gmbh & Co. Kg Elektrische Heizvorrichtung
DE102022109544A1 (de) 2022-04-20 2023-10-26 Eberspächer Catem Gmbh & Co. Kg Elektrische Heizvorrichtung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3458504A (en) * 1966-10-24 1969-07-29 Sterling Drug Inc Steroido(3,4-c)pyrazoles of the 5alpha- and 5beta-androstane series
EP1606307B1 (en) * 2002-07-03 2007-10-24 Ortho-Mcneil Pharmaceutical, Inc. Estrieno[3,2-b]/[3,4-c]pyrrole derivatives useful as modulators of the estrogen receptors

Also Published As

Publication number Publication date
SV2011003817A (es) 2011-05-20
ECSP11010780A (es) 2011-02-28
JP2011528675A (ja) 2011-11-24
EA201100226A1 (ru) 2011-08-30
MX2011000939A (es) 2011-03-04
AR072533A1 (es) 2010-09-01
CR20110045A (es) 2012-05-28
CN102105484A (zh) 2011-06-22
TW201008570A (en) 2010-03-01
EP2307439A1 (en) 2011-04-13
CA2731634A1 (en) 2010-01-28
CL2011000153A1 (es) 2011-07-08
BRPI0915987A2 (pt) 2019-09-24
EP2147924A1 (en) 2010-01-27
WO2010009828A1 (en) 2010-01-28
IL210314A0 (en) 2011-03-31
KR20110036739A (ko) 2011-04-08
DOP2011000024A (es) 2011-02-28
MA32477B1 (fr) 2011-07-03
US20110190246A1 (en) 2011-08-04
PE20110402A1 (es) 2011-06-19
CO6351799A2 (es) 2011-12-20
AU2009273494A1 (en) 2010-01-28
ZA201101445B (en) 2012-07-25

Similar Documents

Publication Publication Date Title
CL2016001809A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x (divisional sol. n° 3344-15).
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
UY32926A (es) Compuestos como antagonistas de los receptores de ácido lisofosfatídico
PH12014501351B1 (en) Fluorinated estrogen receptor modulators and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
CL2013001338A1 (es) Compuestos derivados de benzotieno-piridinas sustituidas, inhibidores de la replicacion del vih; composicion farmaceutica que los comprende; combinacion farmaceutica; kit farmaceutico; y su uso para el tratamiento del vih.
MX2013002975A (es) Moduladores de receptores de estrogenos y usos de los mismos.
PH12015501737A1 (en) Androgen receptor modulators and uses thereof
EA201270815A1 (ru) Модуляторы рецепторов эстрогена и их применение
CL2008002521A1 (es) Compuestos derivados de pirazol sustituidos, antagonista del receptor de androgeno; composicion farmaceutica que comprende a dichos compuestos; y uso del compusto para el tratamiento de cancer.
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
CO6410295A2 (es) Derivados de indol como antagonistas del receptor crth2
DOP2010000234A (es) Antagonistas n,n-disustituidos de aminoalquilbifenilo de receptores d2 de prostaglandina
CL2007000396A1 (es) Compuestos derivados de benzoil-piperidina, moduladores del receptor 5ht2/d3; composicion farmaceutica que los comprende;y su uso en el tratamiento y/o prevencion de patologias delsnc, tales como psicosis, esquizofrenia, depresion, ansiedad,adiccion a drogas y problemas cognitivos.
CL2009001247A1 (es) Compuestos derivados de 5-oxi/amino-indazol; moduladores del receptor de glucocorticoides; el proceso de preparacion de dichos compuestos; composiciones farmaceuticas que los contienen; combinacion farmaceutica; y su uso en el tratamiento de afecciones inflamatorias, trastornos respiratorios, asma y epoc.
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
MY163055A (en) Polycyclic antagonists of lysophosphatidic acid receptors
SV2009003307A (es) Quinazolinas para la inhibicion de pdk1
CL2008002744A1 (es) Compuestos derivados de 1,3-disustituidos-4-fenil-1h-piridin-2-ona, moduladores alostericos del receptor glutamatérgico mglur2; composición farmacéutica y uso de los compuestos en el tratamiento de afecciones neurológicas y siquiatricas mediadas por mglur2.
GT201000153A (es) Agonistas novedosos de los receptores de glucocorticoides
CL2009000873A1 (es) Compuestos derivados de ciclohepta[b]piridina, antagonistas del receptor de cgrp; composicion farmaceutica; y uso para el tratamiento de la migrana.b
GT201700231A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181108